Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2021
Reporting Period: The filing announces financial results for the quarter and full year ended December 31, 2020. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. Specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity are not contained within the text of this Form 8-K.
Material Changes
The filing does not detail specific material changes in financial performance versus prior periods. It references the issuance of a press release containing the Q4 and full-year 2020 results.
Guidance, Outlook, and Management Commentary
- Operational Update: Management provided an update on preclinical results from the Company's exosomes platform during the quarterly earnings call.
- Disclosure: A slide presentation regarding these preclinical results was furnished as Exhibit 99.2 and is available on the Company's investor website.
- Legal Status: The information in this Form 8-K and its exhibits is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2020 financial figures (revenue, net loss, cash position).
- Examine Exhibit 99.2 (Slide Presentation) for details on the exosomes platform preclinical results.
- Verify the Company's cash runway and burn rate, as these are critical for a clinical-stage biotech firm not reporting revenue in this summary.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.